Accelerate Drug Discovery:
Affordable & Effective Medicine for You
Cost implication

Orthodox

Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018 https://jamanetwork.com/journals/jama/fullarticle/2762311

Empowered by Praexisio

  • 1% hit rate increase save the development cost of 25 million USD;
  • Shortening time would save USD 457 thousand per day.
  • One new indication found can compensate the cost of 1.25 billion USD.

Competitior A Competitior IM Competitior XP
FDA-drugs-guided AI Better Accuracy
Multiple conformers for drug screening Better Accuracy
Biochem/Cellular data feedback to the drug design Better Accuracy
Suggesting new indications of existing drugs Bigger Market
Alternative druggable sites search Safety & Efficacy
Generate new compounds from a safer chemical space chemical fragments of FDA-Approved drugs Patent prone
$0.2 B $0.3 B $0.8 B
Providing

AFFORDABLE MEDICINE EFFECTIVE FOR YOU

Multiple conformers for drug screening

Biochem / Cellular data feedback to the drug design

Generate new compounds from a safer chemical space

PATENTABLE

SAFE-BESTEAD Technology

①

AI/MD → docking → AI re-ranking → MD (DRDOCK)

②

Biochem / Cellular data feedback to the drug design

Results

WHAT WE HAVE ACHIEVED

UP TO
88%

Hit rate

UP TO
110X

Biochem Efficacy

UP TO
50X

Cell-Based Efficacy

systemic and integrated solution

Business Model - CRO & Consultancy

Services

Peptide Design & Protein Design

https://www.sciencedirect.com/science/article/pii/S2001037023004415
Latest published
https://www.nature.com/articles/s41467-021-27655-0
https://www.mdpi.com/1999-4923/13/7/927
https://patents.google.com/patent/US20170061288A1/en
Services

Our Customers & Services

學

Multiple conformers for drug screening

醫

Partnerships with University Hospitals

產

Pharma's Extended Drug Design Core

Services

Plagiarism Detection & Academic Integrity

https://ieeexplore.ieee.org/document/10198547
Latest published by Praexisio Scientists
Praexisio

THE Core Team

Sam Wu

Chairman, Co-founder

  • Chairman of Samwell Group.
  • 振動與噪音工程學會 常務理事
  • 計量工程學會 常務監事
  • 中華民國品質學會 會士
  • 美國環境科學會技術委員
  • DMSC成員推動QIF/MBD世界標準
Prof. Lee-Wei Yang

Co-founder

  • Drug Design and Protein Dynamics
  • Directors of IBSB and BAI PhD program, NTHU
  • Honorary Professor, Univ of Liverpool,
  • Visiting Professor, Univ Osaka and Univ Pitt
Prof. Jui-Hung Hung

Co-founder

  • Next Generation Sequencing
  • Department of Computer Science, NYCU
Helen Ling

Voluntary Advisory Board Member

  • Arcadis, Global Brand & Marketing Director
  • British Petroleum Global B2B Brand & Marketing Lead
  • MediaTek Global Branding Director
  • ASUS Global Marketing and Sales
Prof. Chi-Ching, Lee

Scientific Consultant

  • Multi-Omics & Management System & Cloud Services Department of Computer Science, CGU
Prof. Ivet Bahar

Scientific Advisor

  • National Academy of Science Member (USA)
  • Univ of Pittsburgh
  • Univ of Stony Brook
Prof. Carmay Lim

Scientific Advisors

  • Distinguished Researcher, Academia Sinica
Charles Chen

Clinical Pharmacology And Efficacy Consultant

  • Clinical Pharmacology Translational Sciences of Zymeworks
  • Head of Clinical Pharmacology of Travere Therapeutics
Edward Wang

Consultant of Clinical Trials & Development of Industrial Partnership

  • Executive Director, Head Clinical Dev, Field Med Affairs, Global Publ & Med Education, and MIS at Quest Diagnostics
Chen-Hua Lu

Cloud Operation and Businness Develop

  • Heterogeneous Computing, Supercomputing, GPU Applications, and Computational Genomics
  • Founder, Creative Booting Propulsion LTD.
Minjeong Kang

Medical Writor and Global Relationship

  • Samsung Bioepis, Regulatory Affairs, Manager
Praexisio

THE FUNDRAISING TIMELINE

Praexisio

關於普睿思

普睿思股份有限公司 Praexisio Taiwan Inc.

普睿思落實精準醫療（Precision Medicine）的概念，專注發展結合AI輔助和蛋白質分子動態模擬的個人化藥物設計技術 ，精準化新藥抑制疾病的效果，解決因專一性不足新藥難以通過臨床測試的問題。

我們以成為最具品質和專業度的整合型生物資訊顧問服務公司為願景，提供客戶準確到位的問題分析和解決方案。自2020年由清大楊立威教授、交大洪瑞鴻教授及山衛科技吳孝三董事長共同創立至今，團隊集結國際頂尖學者和跨領域工程師，已和美國德州大學西南醫學中心、清華大學、臺北醫學大學、台大醫院等，海內外一流學研單位和醫療機構合作，並於2022年獲得第19屆國家新創獎的肯定。

除了借助前沿的生物資訊技術，提高藥品研發成功率使成本降低，我們 同步開發運用次世代定序打造的致病基因自動化判讀系統 ， 提升複雜疾病診斷的準確率，為患者預劃精準用藥的治療策略。此外，為優化工作效能和把關研究品質， 普睿思開發了高效能運算排程管理系統以及保護使用者隱私的文章相似度比對軟體。我們始終秉持嚴謹的科學素 養和保護原創性的原則，整合投注的資源，進而幫助客戶創造最大的效益。

Praexisio

Contact us

4F-1, No. 25, Lane 169, Kung Ning Street, Si-Chih District, New Taipei City, (221425) Taiwan (R.O.C)
  • 221425 新北市汐止區康寧街169巷25號4樓之1
+886 2-2695-7684
prx_service@praexisio.com.tw
Monday-Friday: 9am to 6pm